Last updated on

Journal of Clinical Oncology
Research Hotspot & Journal Scope - risk


Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.3501
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

Timothy Iveson · Alberto Sobrero · Takayuki Yoshino · Ioannis Sougklakos · Fang-Shu Ou · Jeffery P. Meyers · Qian Shi · Mark P Saunders · Roberto Labianca · Takeharu Yamanaka · Ioannis Boukovinas · Niels Henrik Hollander · Valter Torri · Kentaro Yamazaki · Vassilis Georgoulias · Sara Lonardi · Andrea Harkin · Gerardo Rosati · James Paul ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.9504
United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

Ahmad A. Tarhini · Sandra J. Lee · F. Stephen Hodi · Uma N. M. Rao · Gary I. Cohen · Omid Hamid · Laura F. Hutchins · Jeffrey A. Sosman · Harriet M. Kluger · Vernon K. Sondak · Henry B. Koon · Donald P. Lawrence · Kari Kendra · David R. Minor · Carrie B. Lee · Mark R. Albertini · Lawrence E. Flaherty · Teresa M. Petrella · John M. Kirkwood ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.4_SUPPL.487
Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.

Jérôme Galon · Fabienne Hermitte · Bernhard Mlecnik · Florence Marliot · Carlo Bifulco · Alessandro Lugli · Iris D. Nagtegaal · Arndt Hartmann · Marc Van den Eynde · Michael H. A. Roehrl · Pamela S. Ohashi · Eva Zavadova · Toshihiko Torigoe · Prabhudas S. Patel · Yili Wang · Yutaka Kawakami · Francesco M. Marincola · Paolo A. Ascierto · Bernard A. Fox · Franck Pagès ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2019.37.15_SUPPL.8040
Efficacy and safety of daratumumab, bortezomib, and dexamethasone (D-Vd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk: Updated subgroup analysis of CASTOR.

Katja Weisel · Andrew Spencer · Suzanne Lentzsch · Hervé Avet-Loiseau · Tomer M. Mark · Ivan Spicka · Alberto Bosi · Vania Tm Hungria · Michele Cavo · Je-Jung Lee · Ajay K. Nooka · Hang Quach · Markus Munder · Meral Beksac · Pieter Sonneveld · David Soong · Jon Ukropec · Ming Qi · Maria-Victoria Mateos ·

Medicine
PDF
Journal of Clinical Oncology - DOI: 10.1200/JCO.2020.38.6_SUPPL.TPS383
PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase III trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).

Mary-Ellen Taplin · Martin E. Gleave · Christopher H. Evans · Eleni Efstathiou · Philip W. Kantoff · Ashley E. Ross · Neal D. Shore · Alberto Briganti · Boris Hadaschik · Axel Heidenreich · Oliver Brendan Rooney · Shaozhou Ken Tian · Lisa Wetherhold · Weichun Xu · Shinta Cheng · Sabine Brookman-May · Angela Lopez-Gitlitz · Adam S. Kibel ·

Medicine
PDF

Highly Related Keywords from risk

Research Hotspot

Journal of Clinical Oncology

Research Hotspot
Journal of Clinical Oncology Related Journals

Popular Journals